Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Blinatumomab in refractory myasthenia gravis
NCT06684184Phase 3Not yet recruiting
- Start
- Nov 2024
- Primary completion
- Dec 2025
- Modality
- Antibody Conjugates, scFv Fragments, Bispecific Antibodies
01
Overview
Phase 3, open-label, single-arm trial of blinatumomab in myasthenia gravis (MG). Primary endpoint: Myasthenia Gravis Activities of Daily Living Scale at 12 weeks. Planned start Nov 2024; status: not yet recruiting.
02
Drugs
blinatumomab
03
Conditions
myasthenia gravis (MG)
Beyond the preview
Go deeper on NCT06684184.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06684184.